Bosentan in Children With Pulmonary Arterial Hypertension (FUTURE-1)

Actelion Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Pulmonary Arterial Hypertension

Treatments: Drug: Bosentan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00319267

AC-052-365

2004-005157-63 (EudraCT Number)

Details and patient eligibility

About

The aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that in adults with PAH and to evaluate the tolerability and safety of a pediatric formulation of bosentan in this patient population.

Enrollment: 36 patients

Sex: All

Ages: 2 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent by the parents or the legal representatives.

• Males or females >= 2 and < 12 years of age.

• Idiopathic PAH or familial PAH diagnosed by right heart catheterization (Clinical classification of pulmonary hypertension, Venice 2003).

• World Health Organization (WHO) functional class II or III.

• Oxygen saturation (SpO2) >= 88% (at rest, on room air).

• PAH treatment-naïve patients or patients already treated with either:

  • Bosentan monotherapy
  • Intravenous epoprostenol monotherapy
  • Intravenous or inhaled iloprost monotherapy
  • Combination of bosentan and intravenous epoprostenol
  • Combination of bosentan and intravenous or inhaled iloprost.

• All patients should start the study drug (bosentan pediatric formulation) at 2 mg/kg twice daily (b.i.d.), whether or not they were previously treated with bosentan.

• PAH therapy stable for at least 3 months prior to Screening.

• Stable treatment with calcium channel blockers, if any, for at least 3 months prior to Screening.

• Patient's PAH condition stable for at least 3 months prior to Screening.

Exclusion criteria

• PAH associated with conditions other than idiopathic or familial PAH.
• Non-stable patients, e.g., history (in the last 3 months prior to Screening) of recurrent syncope, or signs and symptoms of non-compensated right heart failure.
• Need or plan to wean patients from intravenous epoprostenol, or intravenous, or inhaled iloprost.
• Body weight < 4 kg.
• Systolic blood pressure < 80%, the lower limit of normal range, according to age and gender.
• AST and/or ALT values > 3 times the upper limit of normal ranges.
• Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
• Hemoglobin and/or hematocrit levels < 75% of the lower limit of normal ranges.
• Pregnancy.
• Known intolerance or hypersensitivity to bosentan or any of the excipients.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

Bosentan

Experimental group

Description:

The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.

Treatment:

Drug: Bosentan